Human polyomavirus 2 Large T antigen (LT)

The Human polyomavirus 2 Large T antigen (LT antigen) is a 708-amino acid multifunctional regulatory protein that is essential for the lifecycle of the JC virus (JCPyV). It acts as a viral helicase and ATPase, orchestrating the replication of the circular double-stranded DNA genome by binding to the viral origin of replication and recruiting host cell machinery. Beyond its role in replication, the LT antigen is a potent oncoprotein that deregulates the host cell cycle by sequestering tumor suppressor proteins such as p53 and the retinoblastoma (Rb) protein family, thereby driving quiescent cells into S-phase to facilitate a productive or transforming infection. In immunocompromised individuals, the reactivation of JCPyV leads to progressive multifocal leukoencephalopathy (PML), a fatal demyelinating disease of the central nervous system where the LT antigen-mediated destruction of oligodendrocytes causes severe white matter lesions. While no direct LT antigen inhibitors are currently FDA-approved, the protein is a primary target for emerging antiviral strategies, including virus-specific T-cell transfers, siRNA-based silencing, and experimental small-molecule helicase inhibitors. Clinically, therapies like checkpoint inhibitors are used to restore the host immune system's capacity to recognize and eliminate LT antigen-expressing cells, although the management of resulting inflammatory complications remains a critical challenge.

Other names

Large tumor antigenLTAgJCPyV Large T antigenJCV T-antigenJC virus Large T antigenLT-Ag

Enhancement of T-cell mediated immune response against viral Large T antigen (via checkpoint inhibition); inhibition of viral DNA replication and helicase activity; competitive or non-competitive inhibition of the ATPase domain; silencing of viral early gene expression (via siRNA/antisense); disruption of LT antigen-mediated cell cycle entry.